ProMIS Neurosciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for ProMIS Neurosciences (PMN).

Price Target Range — 7 Quarters

Analyst Consensus — 6 Analysts

6Buy

Consensus RatingBuy# Analysts6Avg. Consensus PT$52Upside to Avg. PT+1410.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Nov 2, 2026	Roth Capital	Boobalan Pachaiyappan	PT Cut	Buy	$29→$15
Aug 14, 2026	Guggenheim	Yatin Suneja	PT Raise	Buy	$69→$100
Jul 29, 2026	Guggenheim	Eddie Hickman	PT Raise	Buy	$35→$69
Jul 28, 2026	Chardan Capital	Keay Nakae	PT Raise	Buy	$20→$33
Jul 27, 2026	Chardan Capital	Keay Nakae	Initiate	Buy	$20
Jul 8, 2026	Roth Capital	Boobalan Pachaiyappan	Initiate	Buy	$19
Jun 30, 2026	Cantor Fitzgerald	Pete Stavropoulos	Initiate	Overweight	—
Jun 24, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$18
Jun 8, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$18
Feb 6, 2026	Guggenheim	Eddie Hickman	PT Cut	Buy	$125→$35
Dec 1, 2025	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$4→$18
Nov 21, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$100
Nov 18, 2025	Guggenheim	Eddie Hickman	PT Cut	Buy	$150→$125
Jul 14, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Initiate	Buy	$100
May 12, 2025	Maxim Group	Jason McCarthy	Initiate	Buy	$75
Apr 1, 2025	Guggenheim	Eddie Hickman	Maintained	Buy	$150
Feb 26, 2025	Guggenheim	Eddie Hickman	Maintained	Buy	—

Analyst Ratings News

PRO
Roth Capital Maintains Buy on ProMIS Neurosciences, Lowers Price Target to $15

Roth Capital analyst Boobalan Pachaiyappan maintains ProMIS Neurosciences (NASDAQ:PMN) with a Buy and lowers the price target from $29 to $15.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on ProMIS Neurosciences, Raises Price Target to $100

Guggenheim analyst Yatin Suneja maintains ProMIS Neurosciences (NASDAQ:PMN) with a Buy and raises the price target from $69 to $100.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on ProMIS Neurosciences, Raises Price Target to $69

Guggenheim analyst Eddie Hickman maintains ProMIS Neurosciences (NASDAQ:PMN) with a Buy and raises the price target from $35 to $69.

Benzinga Newsdesk

PRO
Chardan Capital Maintains Buy on ProMIS Neurosciences, Raises Price Target to $33

Chardan Capital analyst Keay Nakae maintains ProMIS Neurosciences (NASDAQ:PMN) with a Buy and raises the price target from $20 to $33.

Benzinga Newsdesk

PRO
Chardan Capital Initiates Coverage On ProMIS Neurosciences with Buy Rating, Announces Price Target of $20

Chardan Capital analyst Keay Nakae initiates coverage on ProMIS Neurosciences (NASDAQ:PMN) with a Buy rating and announces Price Target of $20.

Benzinga Newsdesk

PRO
Roth Capital Initiates Coverage On ProMIS Neurosciences with Buy Rating, Announces Price Target of $19

Roth Capital analyst Boobalan Pachaiyappan initiates coverage on ProMIS Neurosciences (NASDAQ:PMN) with a Buy rating and announces Price Target of $19.

Benzinga Newsdesk

ProMIS Neurosciences Inc

ProMIS Neurosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Roth Capital Maintains Buy on ProMIS Neurosciences, Lowers Price Target to $15

PRO
Guggenheim Maintains Buy on ProMIS Neurosciences, Raises Price Target to $100

PRO
Guggenheim Maintains Buy on ProMIS Neurosciences, Raises Price Target to $69

PRO
Chardan Capital Maintains Buy on ProMIS Neurosciences, Raises Price Target to $33

PRO
Chardan Capital Initiates Coverage On ProMIS Neurosciences with Buy Rating, Announces Price Target of $20

PRO
Roth Capital Initiates Coverage On ProMIS Neurosciences with Buy Rating, Announces Price Target of $19

People Also Watch

People Also Watch

ProMIS Neurosciences Inc

ProMIS Neurosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRORoth Capital Maintains Buy on ProMIS Neurosciences, Lowers Price Target to $15

PROGuggenheim Maintains Buy on ProMIS Neurosciences, Raises Price Target to $100

PROGuggenheim Maintains Buy on ProMIS Neurosciences, Raises Price Target to $69

PROChardan Capital Maintains Buy on ProMIS Neurosciences, Raises Price Target to $33

PROChardan Capital Initiates Coverage On ProMIS Neurosciences with Buy Rating, Announces Price Target of $20

PRORoth Capital Initiates Coverage On ProMIS Neurosciences with Buy Rating, Announces Price Target of $19

People Also Watch

People Also Watch

PRO
Roth Capital Maintains Buy on ProMIS Neurosciences, Lowers Price Target to $15

PRO
Guggenheim Maintains Buy on ProMIS Neurosciences, Raises Price Target to $100

PRO
Guggenheim Maintains Buy on ProMIS Neurosciences, Raises Price Target to $69

PRO
Chardan Capital Maintains Buy on ProMIS Neurosciences, Raises Price Target to $33

PRO
Chardan Capital Initiates Coverage On ProMIS Neurosciences with Buy Rating, Announces Price Target of $20

PRO
Roth Capital Initiates Coverage On ProMIS Neurosciences with Buy Rating, Announces Price Target of $19